Pharmaceutical composition and application of same in preparation of medicines used for treating cerebrovascular diseases

A cerebrovascular disease and composition technology, applied in the field of medicine, can solve the problems of reducing the application effect and the like, and achieve the effects of reducing the effective dose, low toxicity, and reduced administration concentration

Active Publication Date: 2013-05-01
NANJING SIMCERE DONGYUAN PHARM CO LTD +1
View PDF1 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

A variety of adverse reactions were observed clinically, including: (1) bleeding tendency; (2) occasional elevation of glutamate-grass transaminase (GOT), glutamate-alanine transaminase (GPT) and blood urea nitrogen (BUN) in the liver and kidney; ( 3) The digestive system occasionally has nausea, vomiting, diarrhea, loss of appetite, and fullness; (4) Allergic reactions: occasionally urticaria, rash, etc.; (5) Circulatory system: occasionally supraventricular arrhythmia, blood pressure drop; (6) Others: occasional headache, fever, pain at the injection site, shock and thrombocytopenia, etc.; These adverse reactions reduce its clinical application effect

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition and application of same in preparation of medicines used for treating cerebrovascular diseases
  • Pharmaceutical composition and application of same in preparation of medicines used for treating cerebrovascular diseases
  • Pharmaceutical composition and application of same in preparation of medicines used for treating cerebrovascular diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0029] Take trans-3-[4-(1H-imidazol-1-ylmethyl)phenyl]-2-propenoic acid sodium 2.50g (grams) [that is, 0.01mol (moles)], add 160g of propylene glycol solution, stir Make it completely dissolved, slowly add water for injection to dissolve it to 1000ml (milliliter), that is to say.

Embodiment 2

[0031] Take (+)-2-camphor 1.54g (ie 0.01mol), add it to 160g of propylene glycol solution, stir to dissolve completely, slowly add water for injection to dissolve to 1000ml, to obtain.

Embodiment 3

[0033] Take 1.54g (ie 0.01mol) of (-)-2-camphor, add it to 160g of propylene glycol solution, stir to dissolve completely, slowly add water for injection to dissolve it to 1000ml, and obtain.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to the field of medicine and discloses a pharmaceutical composition and application of the same in preparation of medicines used for treating cerebrovascular diseases. The pharmaceutical composition comprises trans-3-[4-(1H-imidazole-1-ylmethyl)phenyl]-2-sodium acrylate and 2-borneol.

Description

technical field [0001] The present invention relates to the field of medicine, in particular to a pharmaceutical composition and its application, more specifically to a pharmaceutical composition and its application in the preparation of medicines for treating cerebrovascular diseases. Background technique [0002] Cerebrovascular disease is a group of diseases that seriously endanger human health, and has become one of the important causes of human disability and death. Cerebrovascular disease (CVD for short) refers to brain lesions caused by abnormalities in cerebrovascular vessels. Stroke generally refers to acute cerebrovascular disease. [0003] Cerebrovascular diseases can be simply divided into two categories, one is ischemic cerebrovascular disease caused by the reduction or interruption of blood flow, and the other is hemorrhagic cerebrovascular disease caused by rupture of blood vessels. Ischemic cerebrovascular disease is mainly cerebral infarction (including ce...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/4174A61K31/045A61P9/10
Inventor 张正平杨士豹廖高勇
Owner NANJING SIMCERE DONGYUAN PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap